Biogen Short Interest Ratio and Short Volume

Biogen (NASDAQ:BIIB) Short Interest Frequently Asked Questions

What is Biogen's current short interest?

Short interest is the volume of Biogen shares that have been sold short but have not yet been covered or closed out. As of August 31st, investors have sold 2,380,000 shares of BIIB short. 1.60% of Biogen's shares are currently sold short. Learn More on Biogen's current short interest.

What is a good short interest ratio for Biogen?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Biogen currently has a short interest ratio of 2.0. Learn More on a good short interest ratio for Biogen

Which institutional investors are shorting Biogen?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Biogen: Bank of America Corp DE, Pathstone Family Office LLC, Jefferies Group LLC, Wells Fargo & Company MN, Walleye Trading LLC, Perceptive Advisors LLC, Millennium Management LLC, Pathstone Family Office LLC, Parallax Volatility Advisers L.P., Atom Investors LP, Citadel Advisors LLC, Squarepoint Ops LLC, Bank of America Corp DE, SG3 Management LLC, Perceptive Advisors LLC, Royal Bank of Canada, Credit Suisse AG, Maven Securities LTD, Jefferies Group LLC, Goldman Sachs Group Inc., Allianz Asset Management GmbH, PEAK6 Investments LLC, SG Americas Securities LLC, Simplex Trading LLC, JPMorgan Chase & Co., Twin Tree Management LP, HAP Trading LLC, Susquehanna International Group LLP, BNP Paribas Arbitrage SA, Wolverine Trading LLC, IMC Chicago LLC, Avestar Capital LLC, Cutler Group LP, and XR Securities LLC. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

What is a good short interest percentage for Biogen?

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.60% of Biogen's floating shares are currently sold short.

Is Biogen's short interest increasing or decreasing?

Biogen saw a increase in short interest in August. As of August 31st, there was short interest totaling 2,380,000 shares, an increase of 9.2% from the previous total of 2,180,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

What is Biogen's float size?

Biogen currently has issued a total of 149,033,000 shares. Some of Biogen's outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Biogen currently has a public float of 148,570,000 shares.

How does Biogen's short interest compare to its competitors?

1.60% of Biogen's shares are currently sold short. Here is how the short interest of companies in the sub-industry of "biotechnology" compare to Biogen: Amgen Inc. (1.98%), Gilead Sciences, Inc. (0.00%), Regeneron Pharmaceuticals, Inc. (1.33%), Vertex Pharmaceuticals Incorporated (1.87%), Seagen Inc. (1.45%), Alnylam Pharmaceuticals, Inc. (0.00%), Novavax, Inc. (8.25%), Exact Sciences Co. (0.00%), Repligen Co. (3.08%), and Incyte Co. (2.72%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: Square, Inc. ($9.81 billion), S&P Global Inc. ($7.52 billion), Advanced Micro Devices, Inc. ($7.18 billion), Charter Communications, Inc. ($6.21 billion), Wayfair Inc. ($4.60 billion), Zoom Video Communications, Inc. ($3.23 billion), Uber Technologies, Inc. ($3.11 billion), Palo Alto Networks, Inc. ($2.74 billion), Teladoc Health, Inc. ($2.52 billion), and Etsy, Inc. ($2.16 billion). View all of the most shorted stocks.

What does it mean to sell short Biogen stock?

Short selling BIIB is an investing strategy that aims to generate trading profit from Biogen as its price is falling. Biogen's stock is trading up $1.69 today. To short Biogen stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Biogen will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Biogen?

A short squeeze for Biogen occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of BIIB, which in turn drives the price of the stock up even further.

How often is Biogen's short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including BIIB, twice per month. The most recent reporting period available is August, 31 2021.